Fagron N.V. : North America to drive H2 2023 growth, positive consensus
>Q2 2023 following Q1 2023 trends - Fagron is set to report its H1 2023 results on 3 August. We anticipate that Q2 will follow Q1 dynamics. Regarding EMEA, we expect the pricing cycle to come to an end, which should not have significant benefits in Q2 2023. We believe Fagron will increase its registrations in the second part of the year (note that Fagron did one acquisition in EMEA in Q1 which benefitted the company in terms of registrations). In North America, we exp...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.